Common Contracts
4 similar Master Services Agreement contracts by Checkpoint Therapeutics, Inc., CytoDyn Inc., Immunomedics Inc, Tg Therapeutics, Inc.
MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and CHECKPOINT THERAPEUTICS, INC.Master Services Agreement • November 6th, 2020 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS MASTER SERVICES AGREEMENT (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation having its principal place of business at 2 Gansevoort St., 9th Floor, New York, NY 10014 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and CYTODYN INC.Master Services Agreement • August 14th, 2019 • CytoDyn Inc. • Pharmaceutical preparations • New York
This Master Services Agreement (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between CytoDyn Inc., a Delaware corporation having its principal place of business at 1111 Main Street, Suite 660, Vancouver, WA 98660 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and TG THERAPEUTICS, INC. MASTER SERVICES AGREEMENTMaster Services Agreement • August 9th, 2019 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS MASTER SERVICES AGREEMENT (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between TG Therapeutics, Inc., a Delaware corporation having its principal place of business at 2 Gansevoort St., 9th Floor, New York, NY 10014 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MASTER SERVICES AGREEMENT Between SAMSUNG BIOLOGICS CO., LTD. and IMMUNOMEDICS, INC.Master Services Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This Master Services Agreement (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between Immunomedics, Inc., a Delaware corporation having its principal place of business at 300 The American Rd, Morris Plains, NJ 07950 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
